Regeneron Announces FDA Accepts For Review Libtayo In Combination With Chemotherapy For First-Line Treatment Of Advanced NSCLC - Regeneron Pharmaceuticals (NASDAQ:REGN) - Benzinga

Regeneron Announces FDA Accepts For Review Libtayo In Combination With Chemotherapy For First-Line Treatment Of Advanced NSCLC

byBill HaddadBenzinga Staff Writer

January 19, 2022 5:33 PM

5 seconds read

Take Stock Of The Week Ahead

Get all the latest Share Market trends and news to set you up for the week ahead.

Regeneron Announces FDA Accepts For Review Libtayo In Combination With Chemotherapy For First-Line Treatment Of Advanced NSCLC

© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Comments